ArticleCell2025
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma.
Abstract readClinical Trial, Phase I
In one paragraph
Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial.Nature communications · 2026Trial
- T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells.Nature protocols · 2026Review
- Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Predicting Neoantigen Immunogenicity frombioRxiv : the preprint server for biology · 2026Article
- COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective.Medical sciences (Basel, Switzerland) · 2026Review
- Developing neoantigen cancer vaccines: where are we now?Nature communications · 2026Review
- Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.Science advances · 2026Article
- Role of pyroptosis in melanoma: Molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2026Review
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies.Immune network · 2026Review
- Programming the immunological properties of mRNA vaccines for cancer.Nature reviews. Immunology · 2026Review
- AI-enabled virtual immunopeptidomics links quantitative neoantigen presentation to immunogenicity.bioRxiv : the preprint server for biology · 2026Article
- The promises and challenges of neoantigen cancer vaccines.Nature biotechnology · 2026Review
- Peripheral vaccination-induced brain-resident memory CD8+ T cells durably protect mice against intracranial malignancy.The Journal of clinical investigation · 2026Article
- A structure-informed deep learning framework for modeling TCR-peptide-HLA interactions.bioRxiv : the preprint server for biology · 2026Article
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- Vaccination rescues dysfunctional T cell therapy by amplifying rare stem-like antitumor CD8Research square · 2026Article
- Pipe dream to pipeline: Journey of cancer vaccines and the road ahead.Cell reports. Medicine · 2026Review
- Single-cell differential abundance detection: A new angle on dissecting tumor heterogeneity.World journal of clinical oncology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors.
Eryn BlassDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
Derin B KeskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Computer Science, Metropolitan College, Boston University, Boston, MA 02215, USA; Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, 2800 Lyngby, Denmark.
Chloe R TuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Cleo FormanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Allison VanasseTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Haley E SaxDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Bohoon ShimDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Vipheaviny CheaTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Nawoo KimTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Isabel CarulliTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jackson SouthardTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Haoxiang LyuTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Wesley LuTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Micah Rickles-YoungBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Alexander B AfeyanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
Oriol OliveDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ambica MehndirattaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Haley GreensladeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Keerthi ShettyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Joanna BaginskaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ilana Gomez DiazDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Allison NauDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Kathleen L PfaffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Andrew GansCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Srinika RanasingheCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Elizabeth I BuchbinderDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
Tamara A SussmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
Megan L InscoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
Charles H YoonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Surgery, Brigham and Women's Hospital, Boston, MA 02215, USA.
Scott J RodigHarvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA.
Sachet A ShuklaTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Shuqiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jon C AsterHarvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA.
David A BraunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06511, USA.
Carrie CibulskisBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Nir HacohenBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Massachusetts General Hospital, Krantz Family Center for Cancer Research, Boston, MA 02114, USA.
Donna S NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Anita Giobbie-HurderDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Kenneth J LivakTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Edward F FritschDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Giacomo OliveiraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA.
Jeremy M SimonDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
Patrick A OttDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA. Electronic address: patrick_ott@dfci.harvard.edu.
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6MCancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4MThe Computational Tumor Immunology Core (CTIC)U54CA272688 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Vivek Mittal · 2022 to 2026
$7.4MCancer Immunologic Data Commons (CIDC) Supplement RequestU24CA224316 · NCI · DANA-FARBER CANCER INST · PI CERAMI, ETHAN, MICHOR, FRANZISKA · 2017 to 2022
$6.8MDissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint InhibitionR01CA229261 · NCI · DANA-FARBER CANCER INST · PI Patrick Alexander Ott · 2018 to 2026
$3.8MSystematic identification of minor histocompatibility antigens to address GVHDR01HL157174 · NHLBI · DANA-FARBER CANCER INST · PI HO, VINCENT TRIEN-VINH, KESKIN, DERIN B · 2022 to 2025
$3.0MGenetically engineered mouse model to improve therapy of NUT carcinomaR01CA285308 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Christopher A French, Derin B Keskin · 2023 to 2026
$2.6MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MMerkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapyR01CA279391 · NCI · DANA-FARBER CANCER INST · PI Derin B Keskin · 2024 to 2026
$2.2MSingle cell investigation of co-evolution in cancer cells and host cell immune microenvironmentR50CA251956 · NCI · DANA-FARBER CANCER INST · PI Shuqiang Li · 2020 to 2026
$1.4MNCI NIH HHS P30 CA006516NCI NIH HHS R01 CA229261NCI NIH HHS R01 CA279391NCI NIH HHS R01 CA285308NCI NIH HHS R50 CA251956NCI NIH HHS T32 CA207021NCI NIH HHS U24 CA224316NCI NIH HHS U24 CA224331NCI NIH HHS U54 CA272688NHLBI NIH HHS R01 HL157174
Abstract
Personalized neoantigen-targeting vaccines have demonstrated great promise; however, improved immunogenicity is still needed. Since antigen availability and effective T cell priming are critical for maximal immunogenicity, we tested a synthetic long peptide vaccine formulated with Montanide, poly-ICLC, and locally administered ipilimumab in addition to systemic nivolumab in 10 patients with melanoma. These personalized vaccines generated de novo ex vivo T cell responses against the majority of immunizing neoepitopes in all 9 fully vaccinated patients and ex vivo CD8+ T cell responses in 6 of 9. Vaccination induced hundreds of circulating and intratumoral T cell receptor (TCR) clonotypes that were distinct from those arising after PD-1 inhibition. By linking the vaccine neoantigen specificity of T cell clonotypes with single-cell phenotypes in tumors, we demonstrate remodeling of the intratumoral T cell repertoire following vaccination. These observations show that multi-pronged immune adjuvanticity can boost T cell responses to neoantigen-targeting vaccines.
Indexed as
Adjuvants, ImmunologicAntigens, NeoplasmCancer VaccinesMelanomaCD8-Positive T-LymphocytesFemaleHumansIpilimumabMaleMiddle AgedNivolumabReceptors, Antigen, T-CellAdjuvants, ImmunologicAntigens, NeoplasmCancer VaccinesIpilimumabNivolumabReceptors, Antigen, T-Cellcancer vaccinesimmunotherapymelanomamutationneoantigenpersonalizedT cellvaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.